Rosetta Genomics Reports Rise in Q1 Revenues and Loss; Suspends Guidance

Rosetta Genomics reported revenues of $27,000, following the market introduction late last year of its microRNA-based molecular diagnostic tests.

Full-text access for registered users only. Existing users login here.
New to GenomeWeb? Register here quickly for free access.

Related Stories